BTK and B-cell chronic lymphocytic leukemia: Again, for the treatment of patients with chronic lymphocytic leukaemia (CLL) and haematological malignancies (HM), BTK inhibitor like ibrutinib is the most advanced in clinical development (Aalipour and Advani, 2014; Wang et al., 2015).